Cognition, ADHD Symptoms, and Functional Impairme Neurofibromatosis Type 1

Journal of Attention Disorders 25, 1177-1186

DOI: 10.1177/1087054719894384

Citation Report

#	Article	IF	Citations
1	Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition. Frontiers in Cell and Developmental Biology, 2020, 8, 582220.	3.7	3
2	Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism. Child's Nervous System, 2020, 36, 2285-2295.	1.1	12
3	Clinical characterization of children and adolescents with NF1 microdeletions. Child's Nervous System, 2020, 36, 2297-2310.	1.1	12
4	An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains. Child's Nervous System, 2020, 36, 2321-2332.	1.1	4
5	Cognitive mechanisms of methylphenidate in ADHD: Do improvements in sustained attention mediate behavioral improvements in the natural environment?. Child Neuropsychology, 2021, 27, 425-446.	1.3	2
6	Attention and Motor Learning in Adult Patients with Neurofibromatosis Type 1. Journal of Attention Disorders, 2022, 26, 563-572.	2.6	6
7	Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: A nationwide registerâ€based cohort study. American Journal of Medical Genetics, Part A, 2021, 185, 3706-3716.	1.2	8
8	The mediating role of ADHD symptoms between executive function and social skills in children with neurofibromatosis type 1. Child Neuropsychology, 2022, 28, 318-336.	1.3	2
9	Executive functions and quality of life in children with neurofibromatosis type 1. Orphanet Journal of Rare Diseases, 2021, 16, 420.	2.7	6
10	Atypical NF1 Microdeletions: Challenges and Opportunities for Genotype/Phenotype Correlations in Patients with Large NF1 Deletions. Genes, 2021, 12, 1639.	2.4	10
11	Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. American Journal of Medical Genetics, Part A, 2022, 188, 488-497.	1.2	3
12	Assessing Psychiatric Comorbidity and Pharmacologic Treatment Patterns Among Patients With Neurofibromatosis Type 1. Cureus, 2021, 13, e20244.	0.5	O
13	Auditory Dysfunction Among Individuals With Neurofibromatosis Type 1. JAMA Network Open, 2021, 4, e2136842.	5.9	3
14	Sex- and age-related differences in autistic behaviours in children with neurofibromatosis type 1. Journal of Autism and Developmental Disorders, 2023, 53, 2835-2850.	2.7	2
17	Multidisciplinary neurocutaneous syndrome clinics: a systematic review and institutional experience. Neurosurgical Focus, 2022, 52, E2.	2.3	4
18	A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type $1.$ Neurological Sciences, $0,  ,  .$	1.9	O
20	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30
21	Steady-state visual evoked potentials in children with neurofibromatosis type $1$ : associations with behavioral rating scales and impact of psychostimulant medication. Journal of Neurodevelopmental Disorders, 2022, 14, .	3.1	5

#	Article	IF	CITATIONS
22	Understanding the Neurofibromatosis Type 1 (NF1) experience and the priorities of individuals with NF1 and their caregivers for cognitive and social-emotional research. Journal of Psychiatric Research, 2022, 154, 268-277.	3.1	2
23	The translational genetics of ADHD and related phenotypes in model organisms. Neuroscience and Biobehavioral Reviews, 2023, 144, 104949.	6.1	2
24	Demographic and Disease-Related Predictors of Socioemotional Development in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas: An Exploratory Study. Cancers, 2022, 14, 5956.	3.7	0
25	ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine, 2023, 56, 101818.	7.1	23
27	Delineating Visual Habituation Profiles in Preschoolers with Neurofibromatosis Type 1 and Autism Spectrum Disorder: A Cross-Syndrome Study. Journal of Autism and Developmental Disorders, 0, , .	2.7	0
28	Neuropsychological factors associated with performance on the rey-osterrieth complex figure test in children with neurofibromatosis type 1. Child Neuropsychology, 2024, 30, 348-359.	1.3	O
29	Exploring the biases of the perception of inattention, hyperactivity, and impulsivity of students from parents, teachers, selfâ€reports, and a VR measure. Psychology in the Schools, 2024, 61, 2567-2588.	1.8	0
30	Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study. Journal of Pediatric Psychology, 0, , .	2.1	0
31	The management of neurofibromatosis type $1\ (NF1)$ in children and adolescents. Expert Review of Neurotherapeutics, 2024, 24, 409-420.	2.8	0
32	The Lack of Ad Hoc Neuropsychological Assessment in Adults with Neurofibromatosis: A Systematic Review. Journal of Clinical Medicine, 2024, 13, 1432.	2.4	O